Ad
CLLS Quote Trading Chart Cellectis S.A.
home / stock / clls / clls quote
Quote | Cellectis S.A. (NASDAQ:CLLS)
| Last: | $1.24 |
|---|---|
| Change Percent: | -8.53% |
| Open: | $1.4 |
| Close: | $1.24 |
| High: | $1.4 |
| Low: | $1.14 |
| Volume: | 13,866,430 |
| Last Trade Date Time: | 03/14/2025 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
CLLS Last Twenty Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $1.24 | $1.4 | $1.24 | $1.4 | $1.14 | 13,866,430 | 03-14-2025 |
| $1.29 | $1.3 | $1.29 | $1.33 | $1.27 | 141,479 | 03-13-2025 |
| $1.3 | $1.28 | $1.3 | $1.31 | $1.22 | 121,467 | 03-12-2025 |
| $1.25 | $1.28 | $1.25 | $1.32 | $1.22 | 137,701 | 03-11-2025 |
| $1.22 | $1.26 | $1.22 | $1.29 | $1.2 | 152,895 | 03-10-2025 |
| $1.255 | $1.28 | $1.255 | $1.3097 | $1.25 | 48,755 | 03-07-2025 |
| $1.22 | $1.2531 | $1.22 | $1.2669 | $1.215 | 42,372 | 03-06-2025 |
| $1.28 | $1.31 | $1.28 | $1.31 | $1.28 | 95,268 | 03-05-2025 |
| $1.26 | $1.29 | $1.26 | $1.35 | $1.25 | 76,611 | 03-04-2025 |
| $1.29 | $1.36 | $1.29 | $1.3714 | $1.27 | 81,898 | 03-03-2025 |
| $1.29 | $1.34 | $1.29 | $1.34 | $1.24 | 149,071 | 02-28-2025 |
| $1.33 | $1.4 | $1.33 | $1.4 | $1.32 | 220,782 | 02-27-2025 |
| $1.4 | $1.46 | $1.4 | $1.475 | $1.39 | 59,824 | 02-26-2025 |
| $1.392 | $1.46 | $1.392 | $1.52 | $1.33 | 206,721 | 02-25-2025 |
| $1.498 | $1.52 | $1.498 | $1.55 | $1.47 | 140,728 | 02-24-2025 |
| $1.53 | $1.56 | $1.53 | $1.6 | $1.515 | 76,725 | 02-21-2025 |
| $1.54 | $1.57 | $1.54 | $1.62 | $1.52 | 144,514 | 02-20-2025 |
| $1.54 | $1.53 | $1.54 | $1.61 | $1.5201 | 150,223 | 02-19-2025 |
| $1.575 | $1.53 | $1.575 | $1.62 | $1.51 | 162,987 | 02-18-2025 |
| $1.55 | $1.6099 | $1.55 | $1.6099 | $1.515 | 77,558 | 02-17-2025 |
News, Short Squeeze, Breakout and More Instantly...
Cellectis S.A. Company Name:
CLLS Stock Symbol:
NASDAQ Market:
-8.53% G/L:
$1.24 Last:
13,866,430 Volume:
$1.40 Open:
$1.24 Close:
Cellectis S.A. Website:
Ad
-
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
-
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
-
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...
Important Investor News Alert (OTC: AVAI)
-
LAS VEGAS, NV / ACCESS Newswire / March 10, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), tod...